Tuesday 17 November 2026
Export KYNB’s income statement to Excel — free account
Kyntra Bio Inc
KYNBKyntra Bio Inc’s revenue for fiscal 2025 (year ended December 2025) was $6.4 million, down 78.3% from fiscal 2024.
- Revenue
- n/m
- EPS
- n/m
- Free cash flow
- n/m
Quarter to June 2026, against a year earlier
3.11
0.33
−9.59%
Follow KYNB
Alert me
Where the cash went Q2 FY2026, quarter to 30 June 2026
Free cash flow was −$4.0M: capital expenditures were more than operating cash flow. Cash rose by $13.6M. What is a cash flow statement?
- Free cash flow
- −$4.0M
- Returned to shareholders
- $0.00
- Debt, net
- $0.00 borrowed
- Change in cash
- +$13.6M over the period
| Operating cash flow | 0.0 |
|---|---|
| Free cash flow | 0.0 |
| Acquisitions, net | 0.0 |
| From investments, net | 0.0 |
| Other | 0.0 |
| Change in cash | 0.0 |
Figures in billions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Net Income |
11.97 | (15.20) | (14.22) | 200.64 |
+8 more quarters Free account |
Depreciation & Amortization |
(0.09) | (0.18) | (0.06) | 0.19 | |
Non Cash Items (Other) |
(29.96) | 1.22 | 0.80 | (42.35) | |
Accounts Receivable Change |
4.69 | (4.82) | (0.09) | 0.55 | |
Change in inventories |
0.00 | 0.36 | 0.12 | 1.03 | |
Accounts Payable Change |
2.42 | 1.35 | (1.35) | (4.61) | |
Change in payables and accrued liability |
8.86 | (1.42) | (3.02) | (15.47) | |
Change in other assets and liabilities |
(1.89) | 4.81 | (0.50) | (141.82) | |
Operating Cash Flow |
(3.99) | (13.89) | (18.33) | (1.85) | |
Capital expenditures |
— | — | 0.00 | (0.01) | |
Net Aquisitions |
4.00 | (0.06) | 6.41 | 90.20 | |
Short Term Investments Change (Net) |
(3.95) | (11.05) | (58.12) | (3.03) | |
Long-Term Investments Change (Net) |
17.63 | 14.13 | — | — | |
Other investing activities |
0.00 | — | — | — | |
Investing cash flow |
17.67 | 3.02 | (51.71) | 87.16 | |
Repayment/Issuance of Debt (Net) |
— | — | (0.01) | (80.55) | |
Other financial activities |
0.00 | (0.01) | (0.01) | (5.36) | |
Financing cash flow |
0.00 | (0.01) | (0.01) | (85.92) | |
Exchange Rate Adjustment |
(0.03) | 0.00 | (0.05) | (1.26) | |
Change in Cash |
13.65 | (10.87) | (70.10) | (1.87) | |
Beginning Cash |
0.00 | 47.87 | 0.00 | 0.00 | |
Ending Cash |
13.65 | 37.00 | (70.10) | (1.87) | |
Stock Based Compensation |
0.98 | 1.15 | 1.19 | 0.66 | |
Dividends Paid (Common) |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Cash/Marketcap |
0.00 | 0.00 | 0.00 | 0.00 | |
Assets Liabilities Change (Total) |
14.08 | 0.27 | (4.84) | (160.33) | |
Investments Change (Net) |
13.68 | 3.08 | (58.12) | (3.03) |
In millions of $ except per-share values · columns are period end dates · fundamentals updated 25 Oct 2026